Invitrogen s RNAi Business Growing; Will At Some Point Move to Wisconsin | GenomeWeb

In Invitrogen’s first-quarter conference call, company executives said the company’s RNAi business, which comes from its November 2003 acquisition of Sequitur, is growing.

Although revenue growth was flat for the company’s core genomics business, “our RNAi business is going very strong,” CEO and President Greg Lucier said in the call Thursday. “We are really pleased with the overall Stealth RNAi business and that’s right on track in terms of its performance.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.